文献速递免疫规划传染病防控与疫情报告

17DD黄热病疫苗分剂接种安全性:刚果(金)金沙萨社区药物警戒经验

Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
PubMed 文献 · Vaccine · 2018-09-03

2016年刚果(金)金沙萨预防性接种活动中,对2岁及以上非孕妇接种17DD黄热病疫苗分剂(0.1 ml),通过社区药物警戒收集不良事件。共4020人报告5409例次不良事件,发热和注射部位疼痛最常见,安全性在性别间相似,女性报告腹泻和头晕较多而男性报告乏力较多(P < 0.001)。作者认为分剂接种安全性良好,支持用于疫情控制。

要点

  • 17DD黄热病疫苗分剂(0.1 ml)接种后报告的不良事件以发热和注射部位疼痛为主。
  • 女性报告腹泻和头晕较多,男性报告乏力较多(P < 0.001),总体安全性性别间相似。
  • 4020名报告者中5人报告严重不良事件,其中4人免疫功能较低下。

核心结论

  • 17DD黄热病疫苗分剂(0.1 ml)接种安全性良好,性别间安全性相似。
  • 这些发现补充了已记录的免疫原性特征,支持将黄热病疫苗分剂用于疫情控制。

研究设计与样本

  • 社区层面药物警戒监测,信息通过教堂、学术机构及儿科、产科和友人网络传播。
  • 通过面对面讨论、电话、短信和WhatsApp消息开展免疫接种后不良事件(AEFI)教育并收集报告。
  • 报告录入VigiFlow,使用Stata 12进行统计分析;仅纳入接种分剂者(2岁及以上人群和非孕妇)。
  • 采用比例t检验比较男性和女性之间AEFI首选术语。

主要发现

  • 共4020名受试者报告5409例次AEFI,报告者以男性为主(54.9%),平均年龄26 ± 10.7岁。
  • 发热和注射部位疼痛分别是报告最多的全身性和局部性AEFI。
  • 女性报告腹泻和头晕较多,男性报告乏力较多(P < 0.001)。
  • 5人报告严重AEFI,其中4人免疫功能较低下。

关键数值与推荐

  • 分剂接种剂量为0.1 ml的17DD黄热病疫苗。
  • 分析纳入标准为接种分剂者:2岁及以上人群和非孕妇。

临床怎么用

  • 原文结论认为分剂接种17DD黄热病疫苗安全性良好且性别间相似,支持将分剂接种用于疫情控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In early 2016, there was a Yellow Fever (YF) outbreak in Central Africa with several deaths reported from Angola and the Democratic Republic of Congo. Due to a shortage in vaccine supply, fractional dosing (0.1 ml) of 17DD Yellow Fever Vaccine (YFV) was proposed in preventive vaccination campaign in Kinshasa in August 2016. A Pharmacovigilance surveillance at community level was implemented to track Adverse Events Following Immunization (AEFIs). The objective of this study was to describe AEFIs as captured from community-based pharmacovigilance and to compare the safety profile of the fractional dosing of YFV between gender. METHODS: PV information sessions were organized in churches, academic institutions, and pediatrician, obstetrician and friend networks. Prior to data collection, education about AEFI was provided through face-to-face discussions, phone calls, SMS and WhatsApp messages. Individuals reported AEFIs though the above communication channels to assigned individuals. Reported AEFIs were entered into VigiFlow and extracted for statistical analysis using Stata 12. Only vaccinees who received fractional dose (subjects from the age of 2-year-old and non-pregnant women) were included in analysis. Proportional t-test was used to compare AEFI preferred terms among males and females. RESULTS: A total of 4020 subjects reported 5409 AEFIs. Reporters were mostly males (54.9%) with an average age of 26 ± 10.7 years. Fever and injection site pain were the most reported systemic and local AEFI respectively. The safety profile was similar between gender although females reported more diarrhea and dizziness whilst males reported more asthenia (P < 0.001). Five individuals reported serious AEFIs. Among them, 4 were less-immunocompetent. CONCLUSION: Fractional dosing of 17DD YFV has a good safety profile, which is similar between gender. These findings complement the documented immunogenicity profile to support recommendation of fractional dose of YFV for outbreak control.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nzolo D, Engo Biongo A, Kuemmerle A, et al. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo. Vaccine. 2018. PMID: 30190119. doi:10.1016/j.vaccine.2018.08.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。